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Such disruptions manifest clinically as inability to sleep at night, excessive daytime napping, fatigue, depression, anorexia, and reduced quality of life. Alarmingly, disrupted circadian rhythms predict reduced overall survival in patients with advanced lung, kidney, breast, and colon cancer. At the cellular level, disrupted circadian rhythms are known to adversely affect angiogenesis, 2 apoptosis, 3 and many other biological processes important in cancer. It is well known that melatonin is important as a "timekeeper" for the circadian system, cuing the system to coordinate with environmental light and darkness. Many cancer patients take melatonin supplements for anticancer effects. But recent work suggests that melatonin alone does not reregulate sleep in breast cancer patients. 4 Rather, timing of meals and exercise, strategic light exposure, social support, scheduled sleep times, and potentially drugs that target circadian timing may be needed to intervene to ameliorate cancer patients' disrupted rhythms. 1, 4 Nevertheless, there are studies indicating that high doses of melatonin may improve outcomes of chemotherapy, and numerous studies with melatonin demonstrate its anticancer effects. This suggests that integrative treatment approaches incorporating both lifestyle changes and melatonin may play a large role in circadian cancer therapy.
Integrative Cancer Therapies has been consistently featuring articles on circadian cancer biology since 2009. In that year, we published an entire special issue on circadian rhythms and cancer, guest edited by leading circadian researchers William Hrushesky and David Blask. 5 The special issue contains articles on topics such as tumor suppressor functions of period genes; circadian disruptions and cytokine secretion; circadian effects on breast tumor metabolism; clustering of circadian disruption, fatigue, and anorexia in advanced cancer patients; and practical approaches to circadian therapy. 6 A 2011 systematic review examined the effects of melatonin as an adjuvant to cancer treatment. 7 In 2013, the use of melatonin as a dietary supplement in cancer was discussed. 8 And in 2016 we published the first of a series of 3 studies of the impacts of artificial light at night, which is known to suppress melatonin levels, on the incidence of breast cancer. 9 We hope to see many more articles on the topic of circadian cancer biology published in Integrative Cancer Therapies and elsewhere in the coming years. Integrative therapies have, we believe, a unique role to play in improving the disrupted circadian rhythms of advanced cancer patients, potentially 755916I CTXXX10.1177/1534735418755916Integrative Cancer TherapiesBlock editorial20182018 1 Block Center for Integrative Cancer Treatment, Skokie, IL, USA affecting treatment tolerance, response, life quality, and survival. We plan for this journal to continue to play a major role in disseminating studies and practical information on this topic.
In the first volume of each issue of Integrative Cancer Therapies we acknowledge the expertise and scientific wisdom of an important group of people: those who have participated in our peer review process in the past year. Journal editors know, perhaps better than most researchers, the critical role of peer review in maintaining the quality of scientific publication. The efforts of reviewers have gone for many years with minimal academic recognition, and our publication of the names of reviewers is just a small token of the true value of their time and of the work they put into article reviews. However, Integrative Cancer Therapies is now offering reviewers a way to track and showcase their reviews through the use of the Publons service. Publons is a website (publons. com) that allows reviewers to register each of their reviews, turning them into a measureable research output that can showcase reviewers' expertise and the influence they exert in their fields. Reviewers are now given the opportunity to seamlessly choose to register their Integrative Cancer Therapies reviews with Publons as a part of the review submission process. We hope our reviewers will join the more than 200 000 researchers who have already joined the Publons site, so they can better highlight their contributions to their academic colleagues.
In the meantime, we honor those who participated in our review process during 2017 by listing them below:
